Published in:
Open Access
01-02-2011 | Poster presentation
Therapy with recombinant human antithrombin, heparin and tissue plasminogen activator improves survival and reduces ventilation days in a long-term ovine model of cutaneous burn and smoke inhalation injury
Authors:
S Asmussen, Y Yamamoto, DL Traber, H Ito, R Cox, H Hawkins, LD Traber, D Herndon, P Enkhbaatar
Published in:
Critical Care
|
Special Issue 1/2011
Login to get access
Excerpt
In this study we investigated the long-term effects of a combined therapy with recombinant human antithrombin (rhAT), heparin (hep) and tissue plasminogen activator (tPA) in our established model of acute lung injury, resulting from burn and smoke inhalation injury (BSII). We hypothesised that this triple therapy decreases the requirement of ventilation, reduces ventilation days and improves survival. …